Evidence map›Paper›PMID 32053790›Full record

ArticleCell host & microbe2020

Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.

Surender Khurana, Supriya Ravichandran, Megan Hahn, Elizabeth M Coyle, Spencer W Stonier, Samantha E Zak, Jason Kindrachuk, Richard T Davey, John M Dye, Daniel S Chertow

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA. Electronic address: surender.khurana@fda.hhs.gov.
Supriya RavichandranDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA.
Megan HahnDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA.
Elizabeth M CoyleDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD 20871, USA.
Spencer W StonierUnited States Army, Medical Research Institute of Infectious Diseases, Viral Immunology Branch, Virology Division, Fort Detrick, Frederick, MD 21702, USA.
Samantha E ZakUnited States Army, Medical Research Institute of Infectious Diseases, Viral Immunology Branch, Virology Division, Fort Detrick, Frederick, MD 21702, USA.
Jason KindrachukCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA.
Richard T DaveyDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
John M DyeUnited States Army, Medical Research Institute of Infectious Diseases, Viral Immunology Branch, Virology Division, Fort Detrick, Frederick, MD 21702, USA.
Daniel S ChertowCritical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Center for Biologics Evaluation and Research · USUnited States Army Medical Research Institute of Infectious Diseases · USNational Institutes of Health Clinical Center · USNational Institute of Allergy and Infectious Diseases · US

Funding

Influenza and Emerging Infectious DiseasesZIAAI000984 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DAVEY, RICHARD · 2009 to 2025
$44.1M
Clinical and Molecular Features of Ebola Virus DiseaseZIACL009024 · CLC · CLINICAL CENTER · PI CHERTOW, DANIEL S · 2017 to 2025
$0k
Intramural NIH HHS ZIA CL009024
6 · The paper itself

Abstract

Evolution of antibody repertoire against the Ebola virus (EBOV) proteome was characterized in an acutely infected patient receiving supportive care alone to elucidate virus-host interactions over time. Differential kinetics are observed for IgM-IgG-IgA epitope diversity, antibody binding, and affinity maturation to EBOV proteins. During acute illness, antibodies predominate to VP40 and glycoprotein (GP). At day 13 of clinical illness, a marked increase in antibody titers to most EBOV proteins and affinity maturation to GP is associated with rapid decline in viral replication and illness severity. At one year, despite undetectable virus, a diverse IgM repertoire against VP40 and GP epitopes is observed suggesting occult viral persistence. Rabbit immunization experiments identify key immunodominant sites of GP, while challenge studies in mice found these epitopes induce EBOV-neutralizing antibodies and protect against lethal EBOV challenge. This study reveals markers of viral persistence and provides promising approaches for development and evaluation of vaccines and therapeutics.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralEbolavirusEpitopesHemorrhagic Fever, EbolaHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMiceProteomeRabbitsSurvivorsViral Envelope ProteinsViral Matrix ProteinsAntibodies, NeutralizingAntibodies, ViralEpitopesImmunoglobulin AImmunoglobulin GImmunoglobulin MProteomeViral Envelope ProteinsViral Matrix ProteinsViral ProteinsViral VaccinesVP40 protein, virusaffinityantibodycorrelates of protectionEbolaepitope mappinggenome-fragment phage display libraryGFPDLglycoproteinGPimmune responseinfectionneutralizationvaccinevirus

Identifiers

PMID32053790
PMCPMC7071344
OpenAlexW3006614059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.